Centessa Long Term Debt vs Current Deferred Revenue Analysis
| CNTA Stock | USD 17.04 1.15 6.32% |
Centessa Pharmaceuticals financial indicator trend analysis is way more than just evaluating Centessa Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Centessa Pharmaceuticals is a good investment. Please check the relationship between Centessa Pharmaceuticals Long Term Debt and its Current Deferred Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Centessa Pharmaceuticals PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
Long Term Debt vs Current Deferred Revenue
Long Term Debt vs Current Deferred Revenue Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Centessa Pharmaceuticals Long Term Debt account and Current Deferred Revenue. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Centessa Pharmaceuticals' Long Term Debt and Current Deferred Revenue is -0.46. Overlapping area represents the amount of variation of Long Term Debt that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Centessa Pharmaceuticals PLC, assuming nothing else is changed. The correlation between historical values of Centessa Pharmaceuticals' Long Term Debt and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Long Term Debt of Centessa Pharmaceuticals PLC are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Long Term Debt i.e., Centessa Pharmaceuticals' Long Term Debt and Current Deferred Revenue go up and down completely randomly.
Correlation Coefficient | -0.46 |
| Relationship Direction | Negative |
| Relationship Strength | Very Weak |
Long Term Debt
Long-term debt is a debt that Centessa Pharmaceuticals has held for over one year. Long-term debt appears on Centessa Pharmaceuticals PLC balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on Centessa Pharmaceuticals PLC balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.Current Deferred Revenue
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.Most indicators from Centessa Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Centessa Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Centessa Pharmaceuticals PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. At present, Centessa Pharmaceuticals' Issuance Of Capital Stock is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 758.2 M, whereas Selling General Administrative is forecasted to decline to about 33.9 M.
| 2021 | 2023 | 2024 (projected) | Depreciation And Amortization | 34.0K | 810K | 850.5K | Interest Income | 244K | 10.5M | 11.0M |
Centessa Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Centessa Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Centessa Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Centessa Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Centessa Pharmaceuticals Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Centessa Pharmaceuticals Plc Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Centessa Pharmaceuticals PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Centessa Pharmaceuticals. If investors know Centessa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Centessa Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.52) | Revenue Per Share 0.065 | Return On Assets (0.20) | Return On Equity (0.43) |
The market value of Centessa Pharmaceuticals is measured differently than its book value, which is the value of Centessa that is recorded on the company's balance sheet. Investors also form their own opinion of Centessa Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Centessa Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Centessa Pharmaceuticals' market value can be influenced by many factors that don't directly affect Centessa Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Centessa Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Centessa Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Centessa Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.